p21/Wafl/Cipl cellular expression in chronic long-lasting hepatitis C: Correlation with HCV proteins (C, NS3, NS5A), other cell-cycle related proteins and selected clinical data

Folia Histochemica et Cytobiologica

Volumn 47, Issue 3, 2009, Pages 385-394

  Kasprzak, Aldona ^a   Adamek, Agnieszka ^a   Przybyszewska, Wiesława ^a   Olejniczak, Karolina ^a   Biczysko, Wiesława ^a   Mozer Lisewska, Iwona ^a   Zabel, Maciej ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

ABC and ImmunoMax methods; Long lasting chronic hepatitis C; NS3; NS5A and C protein

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; KI 67 ANTIGEN; MARKER; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PROTEIN C; PROTEIN P21; PROTEIN P53;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CELL CYCLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; FATTY LIVER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER REGENERATION; MALE; PROTEIN EXPRESSION;

HEPATITIS C VIRUS;

EID: 77149172874     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-009-0096-x     Document Type: Article

References (44)

1. Brunt EM, Walsh SN, Hayashi PH, LaBundy J, Di Bisceglie AM. Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma. Liver Internat. 2007;27:662-671.
2. Wafl/Cipl is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases. Hum Pathol. 2002;33:429-434.
3. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol. 2000; 81:1631-1648.
4. Marshall A, Rushbrook S, Davies SE et al. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology. 2005;128:33-42.
5. Safraz S, Hamid S, Siddiqui A, Hussain S, Pervez S, Alexander G. Altered expression of cell cycle and apoptotic proteins in chronic hepatitis C virus infection. BMC Microbiol. 2008;8:133.
6. Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatology Res. 2008;38:1-26.
7. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a potent inhibitor of C1 cyclin-dependent kinases. Cell. 1993;75:805-816.
8. EL-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
9. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131-134.
10. Li R, Hannon GJ, Beach D, Stilman B. Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol. 1996;6:189-199.
11. Luo Y, Hurwitz J, Massague J. Cell cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature. 1995;375:159-161.
12. Macleod KF, Sherry N, Hannon G et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1999;9:935-944.
13. Niculescu III AB, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21Cip1/Waf1 at both the G1/S and G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and preventing endoreduplication. Mol Cell Biol. 1998;18:629-643.
14. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 1994;211:90-98.
15. Wafl/Cipl expression and p53 mutation in hepatocellular carcinoma. Hepatology. 1997;25:575-579.
16. Wafl/Cipl expression is predominantly related to altered p53 in hepatocellular carcinomas. Brit J Cancer. 2000;83:50-55.
17. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner E. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest. 2008;118:3943-3953.
18. 1. Biochem Biophys Res Commun. 2000; 273:479-484.
19. Kao CF, Chen SY, Chen JY, Lee YHW. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene. 2004; 23:2472-2483.
20. Lu W, Lo SY, Chen M, Wu KJ, Fung YKT, Ou JH. Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology. 1999;264:134-141.
21. Otsuka M, Kato N, Lan KH et al. Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J Biol Chem. 2000;275:34122-34130.
22. Dubourdeau M, Miyamura T, Matsuura Y, Alric L, Pipy B, Rousseau D. Infection of HepG2 cells with recombinant adenovirus encoding the HCV core protein induces p21 (WAF1) down-regulation-effect of transforming growth factor beta. J Hepatol. 2002;37:486-492.
23. Yamanaka T, Kodama T, Doi T. Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. Biochem Biophys Res Commun. 2002;294:528-534.
24. Oka K, Nagano-Fujii M, Yoshida I et al. Hepatitis C virus core protein selectively inhibits synthesis and accumulation of p21/Waf1 and certain nuclear proteins. Microbiol Immunol. 2003;47:426-438.
25. Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL. p53-dependent transcriptional repression of p21 (waf1) by hepatitis C virus NS3. J Gen Virol 2001;82:2235-2241.
26. Ghosh AK, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol. 1999;80:1179-1183.
27. Arima N, Kao CY, Licht T, Padmanabhan R, Sasaguri Y, Padmanabhan R. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem. 2001;276:12675-12684.
28. waf, MDM2, p21RAS, and c-ErbB2 in HCV associated hepatocellular carcinoma and adjacent pericarcinomatous foci. J Egypt Nat. Cancer Inst 2002;14:75-85.
29. Scheuer PJ, Standish RA, Dhillon AP. Scoring of chronic hepatitis. Clin Liver Dis. 2002;6:335-347.
30. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem. 1981;29:577-580.
31. Kasprzak A, Adamek A, Przybyszewska W et al. p53 immunocytochemistry and TP53 gene mutations in patients with chronic hepatitis C virus (HCV) infection. Folia Histochem Cytobiol. 2009;47:5-12.
32. Kasprzak A, Adamek A, Biczysko W et al. Intracellular expression of the proliferative marker Ki-67 and viral proteins (NS3, NS5A and C) in chronic, long lasting hepatitis C virus (HCV) infection. Folia Histochem Cytobiol. 2007;45:357-366.
33. Volkmann M, Schiff JH, Hajjar Y et al. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med. 2001;79:594-600.
34. Florese RH, Nagano-Fujii M, Iwanaga Y, Hidajat R, Hotta H. Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus. Virus Res. 2002;90:119-131.
35. nd, Hierholzer C, Ambs S, Billiar TR, Posner MC. Chronic hepatitis C virus infection in humans: induction of hepatitis nitric oxide synthase and proposed mechanisms for carcinogenesis. J Surg Res. 1997;69:321-324.
36. Crary GS, Albrecht JH. Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology. 1998;28: 738-743.
37. rd, Tsuji H, Nozaki I, Murase N, Demetris AJ. An inhibitor of cyclin-dependent kinase, stress-induced p21Waf1/Cip-1, mediates hepatocytes mito-inhibition during the evolution of cirrhosis. Hepatology. 2005;41:1262-1271.
38. Paradis V, Youssef N, Dargere D et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol. 2001;32:327-332.
39. Hiyama H, Iavarone A, LaBaer J, Reeves SA. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene. 1997;14:2533-2542.
40. LaBaer J, Garrett MD, Stevenson LF et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997;11:847-862.
41. Joo M, Kang YK, Kim M-R, Lee HK, Jang J-J. Cyclin D1 overexpression in hepatocellular carcinoma. Liver Internat. 2001;21:89-95.
42. Nishida N, Fukuda Y, Komeda T et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994;54:3107-3110.
43. Slade N, Moll UM. Mutational analysis of p53 in human tumors: immunocytochemistry. Methods Mol Biol. 2003;234:231-243.
44. Kang YK, Kim CJ, Kim WH, Kim HO, Kang GH, Kim YI. p53 mutation and overexpression in hepatocellular carcinoma and dysplastic nodules in liver. Virchows Arch. 1998;423:27-32.